Page 37 - BH-2-3
P. 37

Brain & Heart                                                    Digital tools for stroke and bleeding risk in AF




                 Education   tools   provided?  Yes  No  No       No                             Yes
             Table 4. Comparison of features for understanding the output of each digital tool for estimating stroke and/or bleeding risk in patients with atrial fibrillation (AF)




                 Able to   export/email   results?  Yes (Export)  No  No  Yes (email)            No



                 Able to copy   statements for   EHR?  Yes  Yes  No  No                          No





                 Result   output as   graphic?  Yes  Yes  Yes     No                             No



                 Result   output   as text?  Yes  Yes  Yes        Yes                            Yes




                 What are outcomes stratified   between?  (i) No anticoagulation   (ii) Warfarin   (iii) DOAC  (i) No therapy  (ii) Aspirin  (iii) Aspirin+clopidogrel  (iv) Warfarin  (v) Dabigatran 110  (vi) Dabigatran 150  (vii) Rivaroxaban  (viii) Apixaban  (ix) Edoxaban 30  (x) Edoxaban 60 (i) No oral anticoagulation treatment  (ii) Vitamin K antagonist (iii) Direct oral anticoagulant  (i) No therapy  (ii) Aspirin  (iii) Aspirin+Clopidogrel  (iv) Apixaban  (v) Dabigatr












                 Do outcomes have discrete   categories?  Stroke risk (partitioned   between #/100 of no stroke  event, #/100 for non-disabling   stroke event, and #/100 for   fatal or disabling stroke)  Yes (partitioned between   no risk of stroke, risk of  event with no neurological  deficit, and risk of stroke or   neurological deficit)  Yes (partitioned between   mortality, ischemic stroke   or systemic embolism, and   major bleeding including   hemorrhagic stroke)  Y













                 Statistical measure (s) of   results  Ratio  Annual risk percentage, relative  risk reduction, absolute risk  reduction, and net clinical   benefit for each agent  Percentage (risk-adjusted based  on slide for days after diagnosis   to calculate the risk of the   event)  Stroke:  •   Annual risk of  stoke+thromboembolism by   selected agent  • Relative risk reduction  • Absolute risk reduction  • Chance of benefit per year  Bleeding risk: • Annual risk of









                 Digital tool name  Mayo Clinic   Anticoagulation   Choice Decision   Aid  Stroke Prevention   in Atrial   Fibrillation Risk   Tool (SPARCtool)  GARFIELD-AF   Risk Calculator  ACC   AnticoagEvaluator   Application  CardioSmart   Atrial Fibrillation   and Bleeding Risk   Calculator








            Volume 2 Issue 3 (2024)                         14                               doi: 10.36922/bh.3068
   32   33   34   35   36   37   38   39   40   41   42